Cargando…
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
Immunotherapy is the standard of care for several cancers and the field continues to advance at a rapid pace, with novel combinations leading to indications in an increasing number of disease settings. Durable responses and long-term survival with immunotherapy have been demonstrated in some patient...
Autores principales: | Kluger, Harriet, Barrett, J Carl, Gainor, Justin F, Hamid, Omid, Hurwitz, Michael, LaVallee, Theresa, Moss, Rebecca A, Zappasodi, Roberta, Sullivan, Ryan J, Tawbi, Hussein, Sharon, Elad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016305/ https://www.ncbi.nlm.nih.gov/pubmed/36918224 http://dx.doi.org/10.1136/jitc-2022-005921 |
Ejemplares similares
-
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
por: Atkins, Michael B, et al.
Publicado: (2023) -
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
por: Rizvi, Naiyer, et al.
Publicado: (2023) -
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
por: Kluger, Harriet M., et al.
Publicado: (2020) -
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
por: Tawbi, Hussein A, et al.
Publicado: (2023) -
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)